We are live on
!
Find out more
DM
Deerfield Management Portfolio holdings
AUM
$8.48B
1-Year Est. Return
99.04%
This Fund
S&P 500
This Quarter
Est. Return
+28.39%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$5.06B
AUM Growth
+$953M
(+23%)
Cap. Flow
+$556M
Cap. Flow
% of AUM
10.99%
Top 10 Holdings %
Top 10 Hldgs %
34.58%
Holding
150
New
52
Increased
21
Reduced
21
Closed
24
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$116M |
| 2 |
ONCR
Oncorus, Inc.
ONCR
|
+$66M |
| 3 |
The Oncology Institute
TOI
|
+$56.2M |
| 4 |
Cytokinetics
CYTK
|
+$45M |
| 5 |
Viatris
VTRS
|
+$40M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
IMMU
Immunomedics Inc
IMMU
|
+$196M |
| 2 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$142M |
| 3 |
MYOK
MyoKardia, Inc. Common Stock
MYOK
|
+$96M |
| 4 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$74.4M |
| 5 |
DFPHU
DFP Healthcare Acquisitions Corp. Unit
DFPHU
|
+$58.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 69.84% |
| 2 | Industrials | 0.55% |
| 3 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Viatris
VTRS
$20.1B
| $295M | 5.82% |
15,724,000
+2,450,000
| +18% | +$40M |
|
2
CalciMedica
CALC
$11.6M
| $153M | 3.03% |
377,265
| – | – |
|
3
Centene
CNC
$32.8B
| $146M | 2.88% |
2,430,000
+602,000
| +33% | +$38.2M |
|
|
AFIB
4
DELISTED
Acutus Medical Inc
AFIB
| $125M | 2.47% |
4,341,799
| – | – |
|
5
Larimar Therapeutics
LRMR
$384M
| $110M | 2.18% |
5,144,539
| – | – |
|
|
6
Biogen
BIIB
$30.4B
| $110M | 2.17% |
+448,000
| New | +$116M |
|
|
SWTX
7
DELISTED
SpringWorks Therapeutics
SWTX
| $105M | 2.07% |
1,442,970
+208,708
| +17% | +$13.4M |
|
|
ONCR
8
DELISTED
Oncorus, Inc.
ONCR
| $92.1M | 1.82% |
+2,848,977
| New | +$66M |
|
|
ALXN
9
DELISTED
Alexion Pharmaceuticals
ALXN
| – | – |
-579,248
| Closed | -$74.4M |
|
10
Nkarta
NKTX
$186M
| $87.3M | 1.73% |
1,419,872
-998,900
| -41% | -$41.5M |
|
11
Rhythm Pharmaceuticals
RYTM
$7.31B
| $80.9M | 1.6% |
2,721,203
+824,156
| +43% | +$20.9M |
|
12
AdaptHealth
AHCO
$1.49B
| $67.8M | 1.34% |
1,806,332
+95,658
| +6% | +$2.96M |
|
13
Pacira BioSciences
PCRX
$1.01B
| $62.8M | 1.24% |
1,049,647
-148,178
| -12% | -$8.68M |
|
14
Mirum Pharmaceuticals
MIRM
$7.25B
| $60.2M | 1.19% |
3,448,912
| – | – |
|
|
15
The Oncology Institute
TOI
$535M
| $59M | 1.17% |
+5,460,000
| New | +$56.2M |
|
|
OSH
16
DELISTED
Oak Street Health, Inc.
OSH
| $58.2M | 1.15% |
951,063
| – | – |
|
|
DFPHU
17
DELISTED
DFP Healthcare Acquisitions Corp. Unit
DFPHU
| $56.1M | 1.11% |
5,000,000
-5,460,000
| -52% | -$58.3M |
|
18
Revolution Medicines
RVMD
$39.6B
| $55.3M | 1.09% |
1,396,383
-400,000
| -22% | -$15.8M |
|
|
XLRN
19
DELISTED
Acceleron Pharma
XLRN
| $53.9M | 1.07% |
421,619
| – | – |
|
|
CMAX
20
DELISTED
CareMax, Inc. Class A Common Stock
CMAX
| $53.3M | 1.05% |
+113,958
| New | +$38.3M |
|
21
Fate Therapeutics
FATE
$324M
| – | – |
-668,067
| Closed | -$41.5M |
|
|
22
Cytokinetics
CYTK
$10.9B
| $51.1M | 1.01% |
+2,461,000
| New | +$45M |
|
|
DFHTU
23
DELISTED
Deerfield Healthcare Technology Acquisitions Corp. Unit
DFHTU
| $50.4M | 1% |
3,360,000
| – | – |
|
24
Brookdale Senior Living
BKD
$3.58B
| $48.8M | 0.97% |
11,023,465
-6,696,535
| -38% | -$24.7M |
|
|
BPMC
25
DELISTED
Blueprint Medicines
BPMC
| – | – |
-405,386
| Closed | -$42.7M |
|
Similar funds
FT
GRQ
AV
PCM
VA
QC
IC
NW
Deerfield Management's Q4 2020 Portfolio in Review
As of Q4 2020, Deerfield Management held 150 positions worth $5.06B, up 23% from $4.11B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Deerfield Management deployed $556M of net new capital in Q4 2020, opening 52 new positions and adding to 21 existing holdings. Its largest new stake was Biogen: 448,000 shares worth $110M.
By sector, the portfolio is most concentrated in Healthcare at 70% of assets, up from 62% a quarter earlier, followed by Industrials and Financials.
On the sell side, the largest reduction was DFP Healthcare Acquisitions Corp. Unit, an estimated $58.3M trimmed.
- Deerfield Management's largest Q4 2020 buy was Biogen: 448,000 shares worth $110M.
- Deerfield Management added most to Viatris in Q4 2020, an estimated $40M increase.
- Deerfield Management's biggest Q4 2020 reduction was DFP Healthcare Acquisitions Corp. Unit, cutting an estimated $58.3M.
- Deerfield Management fully exited Immunomedics Inc in Q4 2020, selling an estimated $196M.
- Deerfield Management's ten largest holdings make up 35% of its $5.06B portfolio in Q4 2020.
- Deerfield Management opened 52 new positions and closed 24 in Q4 2020.
- Deerfield Management's portfolio value rose 23% quarter-over-quarter to $5.06B.
Based on Deerfield Management's 13F filing for Q4 2020, filed 16 Feb 2021.